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Abstract
Background: Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the
most common single-gene disorder known to be associated with autism. Despite recent advances in functional
neuroimaging and our understanding of the molecular pathogenesis, only limited neuropathologic information on
FXS is available.
Methods: Neuropathologic examinations were performed on post-mortem brain tissue from three older men
(aged 57, 64 and 78 years) who had received a clinical or genetic diagnosis of FXS. In each case, physical and
cognitive features were typical of FXS, and one man was also diagnosed with autism. Guided by reports of clinical
and neuroimaging abnormalities of the limbic system and cerebellum of individuals with FXS, the current analysis
focused on neuropathologic features present in the hippocampus and the cerebellar vermis.
Results: Histologic and immunologic staining revealed abnormalities in both the hippocampus and cerebellar
vermis. Focal thickening of hippocampal CA1 and irregularities in the appearance of the dentate gyrus were
identified. All lobules of the cerebellar vermis and the lateral cortex of the posterior lobe of the cerebellum had
decreased numbers of Purkinje cells, which were occasionally misplaced, and often lacked proper orientation. There
were mild, albeit excessive, undulations of the internal granular cell layer, with patchy foliar white matter axonal
and astrocytic abnormalities. Quantitative analysis documented panfoliar atrophy of both the anterior and posterior
lobes of the vermis, with preferential atrophy of the posterior lobule (VI to VII) compared with age-matched normal
controls.
Conclusions: Significant morphologic changes in the hippocampus and cerebellum in three adult men with FXS
were identified. This pattern of pathologic features supports the idea that primary defects in neuronal migration,
neurogenesis and aging may underlie the neuropathology reported in FXS.
Background
Fragile X syndrome (FXS) is the most common inher-
ited form of intellectual disability, and the fragile X
mental retardation 1 (FMR1) gene is the most com-
mon single-gene mutation associated with autism
[1-5]. Approximately 30% of individuals with FXS meet
all criteria of the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Version (DSM IV) criteria
for autism as assessed with standardized measures
(Autism Diagnostic Observation Schedule (ADOS) and
Autism Diagnostic Interview, Revised: ADI-R (ADI-R)),
and an additional 30% of those with FXS have PDD
NOS (pervasive developmental disorder, not otherwise
specified) [6].
The FMR1 protein (FMRP) is absent or deficient in
individuals with FXS. FMRP is an RNA-binding protein
that regulates the translation of a number of mRNAs
whose protein products are important for synaptic
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of FMRP, production of many synaptic proteins are dys-
regulated, such as postsynaptic density protein (PSD)95,
Arc (Arg 3.1), matrix metalloproteinase (MMP)9, the a-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
(AMPA) receptor subunits, glutamate receptor (GluR)1
and GluR2, and Ca
2+/calmodulin-dependent protein
kinase (CaMK)II [7-9]. Other proteins regulated by
FMRP are involved with axon guidance and cell motility,
including microtubule-associated protein (MAP)1B and
Semaphorin 3F, suggesting that dysregulation of these
proteins in the absence of FMRP may be related to the
periventricular heterotopia previously reported in some
cases of FXS [10-13]. Furthermore, FMRP interacts with
several proteins that have been identified as potential
candidate genes underlying a number of neurodevelop-
mental disorders, such as the neuroligin family, neuror-
exin 1, SH3 and multiple ankyrin repeat domains
(SHANK 3), phosphatase and tensin homolog (PTEN),
mammalian target of rapamycin (mTOR), PSD95,
Wnt7a and Arc (Arg 3.1) [7,14-20]. A recent report by
Luo et al. [20] demonstrated that FMRP in the mouse
regulates the protein expression of several components
crucial for adult neurogenesis, including cyclin-
dependent kinase (CDK)4, cyclin D1 and glycogen
synthase kinase (GSK)3b. Dysregulation of GSK3b leads
to reduced Wnt signaling pathway activity, which alters
the expression of neurogenin 1 and the fate specification
of adult neuroprogenitor cells.
Despite recent advances in our understanding of the
molecular pathology underlying FXS, only limited neu-
ropathologic information is available (Table 1). To
address this issue, we analyzed the hippocampus and
cerebellum in three men with FXS using histologic,
immunochemical and molecular techniques. Neuro-
pathologic abnormalities were evident in both the hip-
pocampus and the cerebellum of all three cases. The
CA1 region of the hippocampus showed local thickening
and abnormal undulations, and appeared to be enlarged
relative to age-matched, non-FXS control hippocampi.
The cerebellum, particularly lobules VI to VII of the
vermis, was reduced in size and displayed reduced Pur-
kinje cell (PC) density compared with age-matched,
non-FXS controls. These findings correspond to pre-
viously reported studies of individuals with FXS using
magnetic resonance imaging (MRI), in which dys-
morphic, enlarged hippocampi, decreased cerebellar size,
and preferential atrophy of vermal lobules VI to VII
were observed [21-23].
Case histories
Patient 1
This man was the product of a full-term pregnancy. He
had global developmental delay, and was admitted to a
residential facility at 15 years of age, because of difficul-
ties with aggression. He was diagnosed with FXS aged
52 years; the findings of the physical examination
included large prominent ears, a long narrow face and
macroorchidism. At this time, he had a full-scale intelli-
gence quotient (FSIQ) of 34, which had fallen to 22 at
the age of 65 years. A chromosomal analysis at 52 years
of age yielded 23% fragile X-positive metaphases.
The patient was a social individual, who befriended his
caretakers and peers. He repeated words and phrases,
and required no psychotropic medications. Over time,
he developed high blood pressure, prostate cancer and
osteoporosis, and a seizure disorder at 75 years that
required treatment with phenytoin. At the age of
77 years, he was diagnosed with gait ataxia and began
treatment with amantadine, without therapeutic benefit.
Computed tomography (CT) of the brain revealed cere-
bral and cerebellar atrophy and ischemic white-matter
changes. Within the last six months of his life, the
patient was diagnosed with dementia, chronic obstruc-
tive pulmonary disease and a left bundle branch block.
At 78 years, he presented to the hospital with abdominal
pain and ‘coffee-ground’ emesis, and died within
24 hours of admission. Genomic analysis of DNA iso-
lated from post-mortem brain tissue established his full
mutation status, with hypermethylated, full mutation
alleles (CGG repeats of 339, 486, 619, 755, 938, 1225).
Patient 2
This man was the product of a normal pregnancy. He
had developmental delay in early childhood, and had
severe language deficits; he was never able to speak in
full sentences. He was hyperactive and anxious through-
out childhood, and showed excessive rocking, hand-
flapping, poor eye contact, tactile defensiveness and
destructive tantrums, resulting in a diagnosis of autism.
He entered a group home at 30 years of age, where he
required antipsychotic medications for behavior
problems.
On physical examination, he was found to have mitral
v a l v ep r o l a p s e .T h ef a m i l yh i s t o r yi n c l u d e dab r o t h e r
with FXS, and a sister who was a fragile X premutation
carrier and mother of two daughters with FXS. The
patient’s mother had had severe depression in her 40s,
developed unsteady writing and dementia in her 80s,
and was still alive at 94 years at the time of this patient’s
death. The patient died at the age of 57 years despite
resuscitative efforts after choking on food. Molecular
testing on postmortem brain tissue demonstrated the
presence of a full mutation allele (436 CGG repeats).
Patient 3
This man was born after a normal pregnancy, and had
delayed development. His physical features included a
Greco et al. Molecular Autism 2011, 2:2
http://www.molecularautism.com/content/2/1/2
Page 2 of 13long face, prominent ears and macroorchidism. Abnor-
mal behavioral features included anxiety and hand-
biting. The patient was shy but interactive, and he was
able to speak in full sentences. He had savant skills for
trivia, and he had an FSIQ of 57 in adulthood. He lived
in a group home, and was productively employed.
In his fifties, the patient showed increased anxiety and
increased self-abusive behaviors, and he became increas-
ingly rigid in his routines. He developed hypothyroidism
that required levothyroxine, and hyperlipidemia that was
treated with simvastatin.A tt h ea g eo f6 4y e a r s ,t h e
patient developed pain in his abdomen, was diagnosed
with a primary liver neoplasm, and died within 3 months
without a definitive tumor-tissue diagnosis. Southern
blot analysis of DNA isolated from post-mortem brain
tissue showed methylation mosaicism, with a hyper-
methylated, full mutation allele (429 CGG repeats)
present in approximately 72% of the cells, with the
remaining alleles unmethylated, and ranging from
approximately 340 to 440 CGG repeats.
Methods
Pathology
Autopsies
Brain autopsies were performed in accordance with pro-
tocols approved by the University of California-Davis
institutional review board and informed consent was
obtained from family members.
One hemisphere of the fresh brain was cut into coro-
nal blocks 10 mm thick, and frozen at -80°C; the
remaining hemisphere was fixed in 10% phosphate-
buffered formalin. The temporal lobe was separated
from the fixed hemisphere, and serially sectioned
into blocks 5 mm thick for serial embedding of the
Table 1 Documented neuropathology in previously published studies
Author Patient Tissues Brain region
analyzed
Method of
analysis
Microscopical neuropathology
Dunn et al,
1963 [12]
18-year-old man, later
diagnosed with fragile
X syndrome
Brain: 1040 g,
1 normal
cortical pattern, mild
ventricular dilatation
Multiple
regions
LM
2 Inc neurons in subcortical white matter; reduced
myelin in cerebral white matter; siderosis of
globus pallidus, inferior olivary heterotopia,
Rudelli et al,
1983 [59]
23-, 24-week fetuses Brains(2) showing
normal cortical
development; testes
Gross
examination
only
None noted
Rudelli et al,
1985 [60]
62-year-old male Brain: mild cortical
atrophy
Parieto-
occipital
neocortex
LM, Golgi, EM
3 Increased long, thin, immature spines; decreased
synaptic length by EM
Desai et al,
1990 [13]
33-year-old male with
ALS
4
Brain (1850 g) with ALS
pathology; testes
Whole brain LM Heterotopia of olivary nucleus; Subcortical white
matter neuronal clusters
Hinton et al,
1991 [61]
15-, 41-, 62-year-old
male patients (62-year-
old in Rudelli, 1985
[60])
Brains (3):normal Parieto-
occipital
neocortex
Golgi Increased long, thin spines
Cingulate,
temporal
association
cortex
Morphometric
analysis
No significant differences in neuronal counts
Wisniewski,
1991 [62]
63-year-old man Brain: mild atrophy,
hydrocephalus, AVM
5 of
left temporal lobe
Unspecified
neocortex
Golgi Increased long, thin spines
Sabaratnam,
2000 [63]
67-, 87-year-old men 67-year old (1778 g). 87-
year-old: brain enlarged,
ventricular dilatation
87-year-old:
hippocampus,
cerebellum
LM CA4 cell loss, gliosis; PC
6 dropout, Bergmann
gliosis
Irwin et al,
2001[64]
48-, 48-, 73-year-old
men
Brain Temporal and
visual
neocortex
Golgi Increased long, thin spines; increase in spine
density
Moro et al,
2006 [11]
4.5-year-old and
13-year-old boys
Live patients MRI
7 Periventricular heterotopias in both cases
1Brain weights within normal limits unless otherwise noted.
2Light microscopy, standard histologic stains.
3Electron microscopy.
4Amyotrophic lateral sclerosis.
5Arteriovenous malformation.
6Purkinje cell.
7Magnetic resonance imaging.
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Page 3 of 13amygdaloid-hippocampal complex. The blocks were
embedded in paraffin wax and cut into serial sections
5 μm thick. The brainstem was separated from the cer-
ebrum at the level of the midbrain. The cerebrum was
coronally sectioned, the brainstem was sectioned in the
perpendicular plane, and the cerebellum was cut into
sagittal blocks 5 mm thick. The blocks were embedded
in paraffin wax and cut into serial sections 5 μmt h i c k .
Brain sections were inspected grossly for abnormalities.
Sampling for paraffin-wax embedding was performed
for each case as follows: serial sections of the hippo-
campal complex, midline samples of each of the three
vermal lobules, and one section of the lateral posterior
lobe of the cerebellar cortex.
Matched samples were taken from five neurologically
normal controls matched for age and gender (mean ±
SD, 70 ± 9 years, range 60-8) obtained from the autopsy
tissue repository at the University of California, Davis
Medical Center Department of Pathology. Fixation, sam-
pling, processing and staining were equivalent for con-
trol and FXS brains. Post-mortem intervals (PMIs) were,
on average, considerably shorter for the FXS brains than
for controls (FXS 16.3 ± 4.4 hours, range 11.5-20 hours;
controls 52.0 ± 43.6 hours, range 12.5-119 hours).
For the purposes of this study, the vermal lobules of
the cerebellum are referenced as follows: the superior
lobule (lobules I to V of the anterior lobe of the cerebel-
lum), and the posterior (lobules VI to VII) and inferior
lobule (lobules VIII to X) of the posterior lobe of the
cerebellum.
Histology and immunochemistry
All tissue blocks were processed for paraffin-wax
embedding, histochemical staining and immunohisto-
chemistry using previously reported techniques [24]. All
histologic, immunohistochemical and counting techni-
ques were performed on 5 μm thick wax-embedded sec-
tions, as previously reported [24]. Briefly, tissue blocks
were processed for paraffin-wax embedding using stan-
dard techniques. Staining was performed according to
standard methods, using hematoxylin and eosin (H&E)
and Luxol fast blue (LFB) counterstained with periodic-
acid-Schiff (PAS) (for myelin). Silver (modified
Bielschowsky) stain for axons was then used on selected
cases [24]. Immunohistochemical staining using anti-
ubiquitin, anti-glial fibrillary acidic protein (anti-GFAP),
anti-CD68 (KP-1; Dako, Carpenteria, CA, USA), anti-
leucocyte common antigen (LCA/CD-45; DakoCytoma-
tion, Glostrup Denmark) and anti-neurofilament (NF)
(Dako) antibodies was performed using methods
reported previously [24]. Dual-label (myelin basic
protein (MBP)/ubiquitin) immunohistochemistry was
performed using the avidin-biotin procedure, with anti-
MBP antibody (SM 194; Sternberger Monoclonals, Balti-
more, MD, USA) visualized with diaminobenzidine and
anti-ubiquitin antibody (Dako, Glostrup, Denmark)
visualized with Nova Red (Vector Laboratories, Burlin-
game, CA, USA). Appropriate positive and negative con-
trols were employed for each antibody.
Immunofluorescent staining for calbindin
Wax-embedded sections 5 μm thick were dewaxed and
blocked in 10% goat serum (Zymed, San Francisco, CA,
USA) with 0.5% Triton X-100 for 1 hour, followed by
1% non-fat dry milk with 0.1% Triton X-100 for 30 min-
utes at room temperature. Sections were then incubated
with 1:150 anti-calbindin antibody (Chemicon, Billerica,
MA USA) diluted in 1% bovine serum albumin with
0.1% Triton X-100 at 4°C for 48 hours, followed by the
secondary antibody, 1:600 rabbit anti-IgG conjugated
with Alexa 568 (Molecular Probes, Carlsbad, CA USA)
for 1 hour at room temperature. Sections were then
counterstained with 4’,6-diamidino-2-phenylindole (Vec-
tor Laboratories), observed under a microscope (Eclipse
E600, Nikon, Melville, NY, USA) and digitally photo-
graphed (SPOT RTke; SPOT Diagnostics, Sterling
Heights, MI USA).
Estimation of PC density in the cerebellum
Owing to the advanced age of the three patients with
FXS (57, 64 and 78 years) included in the present study,
and to reports of reductions in PC number with norma-
tive aging, counts of the number of PCs in the three
cases of FXS were compared with corresponding counts
in the five age-matched non-FXS cerebella. The areas
evaluated for PC number were from the superior, pos-
terior and inferior vermal lobules, and one section of
the lateral posterior lobe cerebellar cortex, stained for
H&E. In all cases, the portions of the lobules to be ana-
lyzed were marked on the slide before any microscopic
analysis to reduce bias in selection of regions of interest
(ROI), and the experimenter was blinded to the origin
of the tissue sample (that is, which lobule was on which
slide).
PCs were counted within defined ROI in the cerebel-
lum using computer software to outline the ROI and
then randomly select PCs for counting within the ROI
(StereoInvestigator, version 8.0; Microbrightfield Inc.,
Williston, VT, USA). Briefly, at 4× magnification the PC
layer (PCL) was outlined, taking care to not include the
molecular or internal granular cell (IGL) layers. Tracing
of ROI was completed for each of three 5 μmt h i c k
serial sections, separated by 25 μm. The program was
then used to cast a regularly spaced counting grid over
the traced ROI, and individual 25 × 25 μmc o u n t i n g
frames were defined within each grid. PCs within each
of 100 counting frames were then counted at 400× mag-
nification (E-600 microscope, Nikon). PCs were identi-
fied morphologically, and PC nuclei rather than nucleoli
were counted, as nucleoli in the PC do not stain reliably
[25]. Any PC nuclei falling within or contacting the
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whereas any nuclei contacting the exclusion zones were
not counted. After all counting frames were evaluated,
the linear length (in mm) of the PC layer was measured
and recorded. The number of PCs in the PCL and the
linear length of the PCL were used to calculate the
number of PC per mm as described previously [25].
The limited quantity of tissue available (three sections
as opposed to a full serial set through the cerebellum)
prevented a stereologic estimate of total PC numbers.
Therefore, data are presented as the mean number of
PCs counted per millimeter length of the PCL (that is, a
density measurement [25]). In this way, we strove to be
as conservative as possible to ensure that any reduction
in PC number in FXS found would be underestimated
rather than overestimated.
Additionally, as there have been reports of decreased
cerebellar size in FXS [21], foliar cross-sectional width
was measured at 20× magnification using the ‘quick
measure’ line function on the StereoInvestigator soft-
ware. These measurements were routinely taken at the
midpoint of the folia to standardize the relative location
of the measurements. Each measurement was taken thee
times, and the average of the three measurements is
reported. Additionally, each section was evaluated twice
on separate days using the same procedures, and similar
results were obtained.
Molecular measures
Genomic DNA was isolated from 500 mg of frozen cor-
tex and cerebellum from the three patients with FXS
using standard methods (Qiagen, Valencia, CA, USA).
In two cases (patients 2 and 3), DNA was also extracted
from whole blood (3 to 5 ml); results (CGG repeat
sizes) were consistent with those obtained in brain tis-
sue. CGG repeat size and methylation status were deter-
mined using both PCR and Southern Blot analysis using
an image detection system (FluorChem 8800; Alpha
Innotech, San Diego, CA, USA) as previously described
[26]. For Southern blot analysis, 10 μgo fD N Aw e r e
digested with EcoRI and NruI, and the Stb12.3 FMR1
genomic sequence, labeled with Dig-11-dUTP, was used
as a probe. Genomic DNA was also amplified by PCR
using the ‘c’ and ‘f’ primers described by Tassone et al.
[26].
Results
Pathology
Gross examination
The cerebrums of patients 1 and 3 were grossly normal,
with mild cortical atrophy deemed appropriate for age.
Patient 2 had moderate ventricular dilatation, and pro-
minent atrophy of the hippocampus and amygdala. The
cerebella of all three cases appeared generally decreased
in size. On midline sagittal sectioning through the
vermis, both the superior and posterior lobar divisions
were atrophied compared with age-matched control
brains. Of the three patients, only patient 2 showed pre-
ferential atrophy of the posterior lobule by visual inspec-
tion. The inferior lobule appeared the least atrophied of
the vermal lobules in all three patients. Sagittal sections
of the lateral posterior lobe cortex from all patients
showed no obvious atrophy upon visual inspection.
Microscopic examination
Hippocampus Because the structural features of the
CA1/Sommer sector of the hippocampus were oversha-
dowed by ischemic changes in patient 2, we limited our
analysis of hippocampal microscopic structure to
patients 1 and 3. In both cases, in several sections
throughout the hippocampus evaluated, CA1 had similar
abnormalities in the microanatomic organization of the
pyramidal cell layer. There was a bulge or expansion
composed of increased numbers of pyramidal cells
(Figure 1) arranged in an undulating pattern. In neigh-
boring regions, there appeared to be a reduction in pyr-
amidal cell number. In all three cases, the penetrating
cortical arterioles of the temporal cortex showed vascu-
lar hyalinosis. These vessel walls were negative for amy-
loid birefringence with Congo red stain, and showed
faint staining with ß-amyloid antibody (not shown).
Immunostaining was negative in brain parenchyma for
b-amyloid, a-synuclein, ubiquitin and tau, stains that
are routinely used for the neuropathologic diagnosis of
the most commonly occurring neurodegenerative disor-
ders, such as Alzheimer’s disease, Lewy Body disease
and frontotemporal dementia.
Cerebellum Histopathologic abnormalities identified by
H&E stain in the vermal lobules and the lateral poster-
ior cerebellar cortex were similar in all three patients.
Prominent, patchy loss of PC could be visualized with
either H&E or calbindin stains. Quantitative analyses
r e v e a l e dad e c r e a s eo fm o r et h a n4 0 %i nt h en u m b e ro f
PC (Figure 2) in all vermal lobules and lateral cortical
sections compared with age-matched controls. Existing
PCs were frequently clustered, and within these small
groups, often lacked proper orientation. Compared with
age-matched normal controls, there were increased
numbers of PC in the IGL. Bergmann glia were present
in expected numbers, and showed no increase in cyto-
plasmic staining for GFAP, contrary to what would be
expected in Bergmann gliosis. There were small num-
bers of scattered GFAP-positive astrocytes in folia that
demonstrated mildly expanded cytoplasmic borders;
however, these changes fell short of those seen with
either reactive or gemistocytic astrocytic morphology.
Vellate astrocytes of the IGL showed no changes on
GFAP immunostaining. Myelin staining (LFB-PAS)
showed mild patchy pallor, most often in distal foliar
white matter. NF staining revealed foci of scattered,
Greco et al. Molecular Autism 2011, 2:2
http://www.molecularautism.com/content/2/1/2
Page 5 of 13Figure 1 Hippocampal formation. Images of the hippocampal formation at the level of the lateral geniculate body from (A) patient 1 and
(C) patient 3 show abnormal expansion of CA1 by increased numbers of pyramidal neurons. These are compared with the more usual
hippocampal microarchitecture that shows a thinner linear band of neurons in CA1, as seen in (B) a 62-year-old male control. Haematoxylin and
eosin, original magnification ×10; scale bar = 1 mm. Arrow indicates bulge/expansion composed of increased numbers of pyramidal cells in
(A) patient 1 and (C) patient 3.
Figure 2 Abnormalities in the cerebellum. Histologic abnormalities seen in FXS cerebella. (A) Decreased numbers of Purkinje cells (PCs) and
clusters of PCs (arrows) in which cells are often misoriented. Haematoxylin and eosin, original magnification ×200; scale bar = 200 μm. (B) Patchy
pallor of foliar white matter and increased variability in thickness of the internal granular cell layer (IGL). Arrows indicate foci of myelin pallor. Luxol
fast blue-periodic-acid-Schiff (LFB-PAS), original magnification ×200; scale bar = 1 mm. (C) Diffuse axonal loss in cerebellar foliar white matter (FWM)
(neurofilament immunohistochemistry, original magnification ×100; scale bar = 400 μm); (D) Activated astrocytes in foliar white matter, a finding
not seen in deep cerebellar white matter. Arrows indicate abnormal astrocytes. (glial fibrillary acidic protein immunohistochemistry, original
magnification ×200; scale bar = 200 μm). (E) Vascular hyalinosis within foliar white matter, as indicated by arrows. LFB-PAS, original magnification
×200; scale bar = 200 μm. (F) High magnification of foliar white matter axonal abnormalities that include axonal loss (arrowheads) and swollen
axons, as indicated by arrows. Neurofilament immunohistochemistry, original magnification ×400; scale bar = 100 μm.
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regions of myelin pallor. Within the distal foliar white
matter, there were scattered white-matter small vessels
with prominent hyalinosis of their walls, which were not
seen in controls.
Based on the improved characteristics of calbindin
antibody staining over standard Nissl stains as a marker
for PCs in postmortem human brains [25], we used cal-
bindin immunofluorescence (IF) to evaluate the mor-
phology of PCs and to confirm any reductions in cell
number identified in H&E-stained cerebella. In age-
matched controls (Figure 3), calbindin-immunoreactive
PCs were spaced regularly, although somewhat variably,
depending on the plane of the section, and the dendrites
of control PCs had fine processes from their dendritic
trees. By contrast, the three patients had a substantial
reduction in calbindin-immunoreactive PCs, with
attenuation of dendritic arborization. Similar features
were seen throughout the vermis and lateral cortex.
PC density in the cerebellum
Based on the cell-density measurements performed in
the present study, there was a 52% reduction in PCs
per mm in the superior lobule, a 54% reduction in the
posterior lobule, a 49% reduction in the inferior lobule
and a 58% reduction in the lateral cortex sample, com-
pared with control cerebellar sections. There was no
numerical overlap between counts of PCs between the
cases and controls; all patients with FXS had clear
reductions in PC density in all cerebellar regions evalu-
ated (Figure 4A-D). These results suggest a global
Figure 3 Calbindin immunofluorescent staining in the cerebellar cortex. Calbindin immunofluorescent staining of the cerebellar cortex
indicates decreased numbers of PCs and diminished complexity of the PC dendritic arborization compared with age-matched controls. Similar
changes were observed in all vermal lobules and in lateral posterior lobe cortex. (A) Vermal inferior lobule and (B) lateral posterior lobe
cerebellar cortex. Original magnification ×10; scale bar = 250 μm.
Greco et al. Molecular Autism 2011, 2:2
http://www.molecularautism.com/content/2/1/2
Page 7 of 13reduction in PC number in the patients with FXS rela-
tive to the age-matched non-FXS controls. This reduc-
tion in PC number was supported by the calbindin IF
results.
To further study possible microscopic correlates to
previously observed MRI abnormalities in the cerebellar
vermis in FXS, we obtained simple measurements of
foliar width. There were no dramatic reductions in foliar
widths in the superior and inferior vermal lobules (0%
and 7% reduction, respectively, relative to controls);
visual inspection of this data revealed a large overlap in
foliar widths between cases with FXS and controls (Fig-
ure 5A-D). However, there was a dramatic reduction in
foliar width in the posterior lobules (21% reduction) and
in the lateral cortex of the cerebellum (20% reduction)
compared with controls. Foliar width measurements of
the inferior lobules gave similar values to controls for
patients 1 and 3. Patient 2 also had reduced foliar width
in the inferior lobule, (Figure 5C). There was no numer-
ical overlap between patients with FXS and controls; all
cases with FXS had clearly reduced foliar widths in the
lateral cortex and the posterior lobule compared with all
of the controls evaluated. These data suggest that
lobules VI to VII are decreased in size in FXS compared
with non-FXS controls, but that lobules I to V and VIII
to X appear to be the same size as non-FXS controls,
consistent with published MRI findings, which identified
a similar pattern.
Figure 4 Purkinje cell counts in the cerebellum. Purkinje cell (PC) counts in: (A) superior lobule; (B) posterior lobule; (C) inferior lobule; and
(D) lateral cortex, in the three fragile X cases and age-matched controls.
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We have identified novel microscopic abnormalities in
the hippocampal formation and cerebellar vermis in
three aged men with FXS. These offer correlations with
established MRI changes in these structures in indivi-
duals with FXS. Neuroimaging studies of FXS have
shown enlargement of the hippocampi [21,22,27,28] and
decreased cerebellar size, particularly the posterior lobe
of the cerebellum. In patients 1 and 3, the CA1 pyrami-
dal cell layer of the hippocampus was focally enlarged
and widened (Figure 1). Such microscopic malforma-
tions of the hippocampus have rarely been identified in
the medical literature. ‘Tectonic hippocampal malforma-
tion’, described to date only in temporal lobe epilepsy
[29], appear similar to the hippocampal pathology we
found. It is likely that this finding in FXS may be related
to abnormalities in adult neurogenesis, as FMRP defi-
ciency has been reported to increase the early prolifera-
tion of both stem and progenitor cells in addition to
reducing the survival rate of young neurons [20]. In
addition, the loss of FMRP down-regulates the Wnt
pathway, which is important for cell proliferation in the
hippocampus [20]. Therefore, focal proliferation adja-
cent to focal cell loss, representing a focal dysplasia,
Figure 5 Foliar diameter in the cerebellum. Foliar width measurements in: (A) superior lobule; (B) posterior lobule; (C) inferior lobule; and
(D) lateral cortex, in the three fragile X cases and age-matched controls.
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teins in the absence of FMRP. The dysregulation of the
Wnt pathway in the absence of FMRP also relates to
dysregulated neural migration that appears to underlie
some neuropathologic features of FXS [11].
The first neuroanatomical abnormality in FXS visua-
lized by MRI was the decreased size of the posterior
lobe of the cerebellar vermis [30]. Using MRI, Gothelf
et al. [23] studied 84 children with FXS who ranged in
age from 1.1 to 22.7 years (range 11.7 ± 5.7) and
72 age-matched controls, and found that size of the pos-
terior lobe of the vermis (lobules VI to X) correlated
positively with FSIQ and FMRP levels. Particular atro-
p h yo fl o b u l e sV It oV I Io ft h ev e r m i so nM R Ih a sa l s o
been described [23,30]. Our measurements of foliar
width support these previous studies by demonstrating
decreased width of the folia in the posterior lobule com-
pared with the adjacent superior and inferior lobules.
We have also identified a 40% reduction in PCs in the
vermis and in a limited analysis of the cortex of the lat-
eral posterior lobe. In all areas of cerebellum examined,
there was disorientation and misplacement of PC, mild
conformational changes in the microscopic appearance
of the IGL, and axonal and myelin pathology in the
foliar white matter.
Decreased cerebellar vermis size is a common finding
in other neurodevelopmental disorders, including atten-
tion deficit hyperactivity disorder (ADHD), autism,
22q11.2 deletion syndrome (velocardiofacial syndrome),
Joubert syndrome and schizophrenia [31-36]. Addition-
ally, PC count is reduced in some cases of autism
[25,36-38], and PC size is reduced in schizophrenia
[39,40]. In addition to a reported negative correlation
between vermis volume and autistic tendencies in both
autism and FXS [38,41], it is suggested that the vermis
may modulate emotion in schizophrenia, and underlie
some of the pathogenesis behind the disease [39]. Hessl
et al. [27] suggested that a subset of behavioral irregula-
rities seen in FXS, such as perseverative speech, hyper-
activity, tactile defensiveness, language dysfunction and
attention deficits, could be related to improper function-
ing of the cerebellar vermis.
Studies on schizophrenia and autism have also
revealed features in the hippocampal formation and cer-
ebellum consistent with migration disorders. Heteroto-
pic displacement and aberrantly clustered neurons,
particularly pre-alpha cells, in laminae II and III have
been reported in the schizophrenic entorhinal cortex
[42-44]. Owing to the interconnections of the entorhinal
cortex and hippocampus, and its connections to other
cortical areas, such migration abnormalities could con-
tribute significantly to the neuropsychologic deficits in
schizophrenia [42]. Cases of autism have been reported
in which heterotopic cells were observed in the
cerebellar molecular layer [37], in the white matter of
the anterior cingulate gyrus and inferior frontal gyrus, in
the hippocampus, the wall of the lateral ventricle [45]
and lateral to the olivary bodies [46]. However, these
findings in autism are limited because of a dearth of
available tissue. In addition, conflicting evidence has
arisen from other studies attempting to replicate the
findings in schizophrenia [47-49]. It is interesting that a
recent report of FMRP levels in neuropsychiatric disor-
ders without an FMR1 mutation demonstrated very low
levels of FMRP in the brains of people with schizophre-
nia [50] and people with autism [51]. Therefore, low
levels of FMRP in both autism and schizophrenia would
be likely to lead to an overlap or commonality of neuro-
pathologic findings between these disorders and FXS.
The FMR1 gene has been implicated in neuronal
migration anomalies [11]. Specifically, there have been
previous observations of periventricular heterotopia in
neuropathologic studies of FXS [12,13], and on magnetic
resonance imaging (MRI) scans in two cases of FXS
[11]. The absence of FMRP has been reported to dysre-
gulate molecules involved in axon guidance and mobi-
lity, including Wnt 7a, semaphorin 3F and MAP1B,
possibly leading to migration abnormalities similar to
those we report here [10,11,17,20]. A recent study of the
cytoplasmic FMR1 interacting protein (CYFIP1) bacterial
artificial chromosome (BAC) transgenic mouse, which
over-expresses CYFIP, demonstrated similar disorienta-
tion and misalignment of the PCs in addition to
abnormalities of the dendritic tree detected by Golgi
staining, similar to our findings with calbindin staining
[52]. CYFIP is regulated by FMRP, and it is an interact-
ing protein with FMRP that is crucial to the repression
of proteins important for synaptic plasticity by FMRP
[53]. Expression of CYFIP is dysregulated in FXS [54].
Further investigation is therefore warranted to elucidate
prenatal or perinatal migratory mechanisms involved in
FXS, autism and other neurodevelopmental disorders.
Our findings provide insight into the structural corre-
lates that relate to functional deficits involving the cere-
bellum in FXS. The decreased density of PCs, which
constitute the primary efferents from the cerebellar cor-
tex, in these older men may be related to (or result
from) abnormal GABAergic transmission and disrupted
cortical-cerebellar connectivity [55,56]. The cerebellum
is the site of termination of the spinocerebellar pathway,
which carries subconscious proprioception [27]; and is
thus involved in motor functions including the relation
of external responses to a person’s own acts, and the
ability to expect the outcomes of particular movements,
which are impaired in FXS [27]. A recent study of the
medical and neurologic problems of aging in FXS in
over 60 individuals demonstrated a high rate of motor
problems including parkinsonian features of tremor and
Greco et al. Molecular Autism 2011, 2:2
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Page 10 of 13ataxia [57]. In addition, the recent report of the role of
FMRP in neurogenesis has shown deficits in neurogen-
esis in cells with an absence of FMRP [20]. These find-
ings may have significant effects on the aging process of
those with FXS and should stimulate further neuro-
pathologic studies in FXS.
Conclusion
Our neuropathologic analysis of post-mortem CNS tis-
sue from three patients with FXS provides clear evi-
dence of cytoarchitectural abnormalities of the aging
brain in individuals with FXS. We speculate that these
abnormalities may reflect defects in neuronal migration
and neurogenesis, and neuronal function and mainte-
nance in aging individuals [58]. Our results also reveal
microscopic pathologic features in FXS brains that
overlap with those reported in cases of autism and schi-
zophrenia. These similarities suggest that shared patho-
genic mechanisms may underlie these developmental
disorders, and the recent reports of low FMRP in the
brain of people who have died from schizophrenia or
autism further supports this concept [50,51]. Additional
neuropathologic studies may also identify a degenerative
component that corresponds to the clinical neurologic
deterioration often seen in individuals with FXS as they
age [57]. The results from the current study warrant
more comprehensive studies on a larger population of
cases with FXS, which requires a coordinated effort in
collecting and studying these brain samples. Our hope is
that correlation of this information with molecular and
clinical studies will increase our understanding of this
and other genetic disorders, and result in early treat-
ment that may diminish or nullify the developmental
and aging effects of this genetic disorder.
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